Anavex 2-73 is being investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It functions as a sigma-1 receptor agonist, which is believed to play a role in cellular stress regulation and neuroprotection. By modulating this receptor, Anavex 2-73 aims to reduce neuronal damage, improve cognitive function, and slow disease progression. Clinical trials are ongoing to evaluate its efficacy in improving memory, learning, and overall quality of life in patients with Alzheimer's. Additionally, research is exploring its potential benefits in other conditions such as Parkinson's disease and Rett syndrome, given its neuroprotective and anti-inflammatory properties.